BACKGROUND: Genotype has been implicated in the outcome of ovarian stimulation. The analysis of patient-specific genotypes might lead to an individualized pharmacogenomic approach to controlled ovarian stimulation (COS). However, the validity of such an approach remains to be established.
Introduction
Ideally, a tailored approach to controlled ovarian stimulation (COS) in infertile patients would involve a comprehensive evaluation of the patient's characteristics, including genotype profile. Pharmacogenomics evaluates how genes influence individual responses to medication. Pharmacogenomic approaches appeared to be a cost-effective strategy in several medical fields (Patel et al., 2014; Mizzi et al., 2016) . Data regarding the clinical utility of pharmacogenomics in ART are still scanty . Nonetheless, increasing evidence indicates that specific genetic characteristics of gonadotrophins and their receptors could influence the ovarian response to exogenous gonadotrophins. Specifically, a common single nucleotide polymorphism (SNP) of the FSH receptor (FSHR, rs6166) has been associated with increased FSH consumption during COS (Yao et al., 2011) . It has also been associated with increased basal levels of FSH, which suggests an impaired response to both endogenous and exogenous gonadotrophins (Perez Mayorga et al., 2000; Behre et al., 2005; Simoni and Casarini, 2014; Alviggi et al., 2016a) . Moreover, a FSHR polymorphism at position −29 (FSHR, rs1394205) was found to be associated with a poor ovarian response (Achrekar et al., 2009b) . Similarly, a suboptimal response to IVF was observed in SNP carriers of the gene encoding the LH beta subunit (Alviggi et al., 2011 . Recently, LH receptor SNPs (LHCGR, rs2293275 and LHCGR, rs12470652) were reported to affect COS and ART (O'brien et al., 2013; Lindgren et al., 2016; Alviggi et al., 2016b) . These findings prompted the hypothesis that a 'hypo-response' to gonadotrophin therapy could be related to specific genotype characteristics (Alviggi et al., 2016a ).
Contrary to poor-responders, 'hypo-responders' have a good prognosis for ART in terms of basal characteristics and ovarian reserve, but require a higher-than-expected dose of gonadotrophins and more prolonged stimulation to obtain an adequate number of oocytes .
Given the steady increase in evidence that SNPs affect COS and ART outcomes, we conducted a systematic review and meta-analysis data in the attempt to summarize the clinical evidence regarding the impact of polymorphisms of gonadotrophins and their receptors on the outcome of COS.
Methods

Protocol and registration
This study was exempt from institutional review board approval because it did not involve human intervention. We adhered to the Preferred Reporting Items for Systematic Reviews and Meta-analysis and provide its checklist in the Supplementary material. The study protocol was registered at http://www.crd.york.ac.uk/PROSPERO/ (registration number CRD42016050402) on 31 October 2016, before starting the review process.
Eligibility criteria
We used the PICO (Patients, Intervention, Comparison and Outcomes) model to select our study population. We included only women who underwent COS, and evaluated COS outcomes according to individual genotype expression (Supplementary Table I ).
Search strategy
We conducted a systematic search using the MEDLINE (PubMed), EMBASE, SCOPUS and Cochrane Library databases to identify all relevant studies published before January 2017. Combinations of the following keywords and MESH search terms were used: 'COH', 'COS', 'controlled ovarian stimulation', 'ART', 'IVF', 'ICSI', 'FIVET', 'IUI', 'intrauterine insemination', 'ovulation induction', 'polymorphism' OR 'SNP' 'luteinizing hormone/choriogonadotropin receptor' 'LHCGR', 'FSH Receptor', 'FSHR', 'FSH', 'follicle-stimulating hormone', 'follicle-stimulating hormone, beta subunit', LH', 'luteinizing hormone' and 'luteinizing hormone, beta subunit'. No time or language restrictions were adopted, and queries were limited to human studies. The reference lists of relevant reviews and articles were also hand-searched.
Selection of studies
Two reviewers (A.C. and D.S.) independently evaluated titles and abstracts. Duplications were removed using Endnote online software and manually. Disagreements were resolved by discussion among authors, and if required, with the involvement of the most experienced authors (C.A., S.E., C.Y.A, P.H, G.D. and M.S). Only clinical trials published in peer-reviewed journals were evaluated. Case series, case reports, book chapters, congress abstracts and gray literature were not included.
Data extraction
Data were extracted independently by two reviewers (A.C. and D.S.) using predefined data fields, and study quality indicators. Discrepancies were resolved by discussion with the senior authors (C.A., S.E., C.Y.A., P.H, G.D. and M.S.).
Risk of bias, summary measures and synthesis of the results
The risk of bias and the quality of the studies included in this meta-analysis were evaluated. Two authors (A.C. and D.S.) independently assessed the risk bias of each study. The senior authors (C.A., S.E., C.Y.A., P.H., G.D. and M.S.) resolved conflicts. The Newcastle-Ottawa scale (NOS) score was used to evaluate the studies included, and judgment on each one was passed according to three issues: selection of the study group, comparability between groups and ascertainment of exposed/not exposed cohorts (Wells et al., 2004) .
The primary outcome was the number of oocytes retrieved. Secondary outcomes were: FSH consumption, stimulation duration (number of days of gonadotrophin use for COS), the number of metaphase II (MII) oocytes and ongoing pregnancy rate (OPR). OPR was defined as a pregnancy diagnosed by ultrasonographic visualization of at least one gestational sac. Bias across studies regarding the primary outcome was assessed using visual inspection of funnel plots, the trim and fill method (Duval, 2006) and the Egger test (Egger et al., 1997) .
Quantitative analysis
Statistical analysis was carried out using Review Manager 5.3 (The Nordic Cochrane Centre, The Cochrane Collaboration). Categorical data were combined with a pooled odds ratio (OR) using the Mantel-Haenszel method. Continuous data were combined with weighted mean difference (WMD) using the inverse variance method. When at least three studies were available, a meta-analysis was conducted using the fixed-effect model. The random-effect model was used in case of significant heterogeneity among studies. Heterogeneity was assessed using the percentage of total variation in the estimated effect across studies (I 2 ). An I 2 value > 50%
indicates substantial heterogeneity. P-values <0.05 were considered statistically significant. We applied Bonferroni correction in case of statistical significance. Subgroup analysis by type of exogenous FSH (i.e. recombinant versus urinary) was conducted to assess potential sources of heterogeneity in the number of oocytes retrieved. We also evaluated differences in FSH basal level in relation to FSHR 919 G>A (rs6165) and FSHR 2039 G>A (rs6166) genotype distribution. Sensitivity analysis was carried out to assess the leverage of studies with a low risk of bias (NOS ≥ 6) on the results. For the primary outcome, an additive effect of genotypes was also tested. Using the R statistical package (R Foundation for Statistical Computing, Vienna, Austria), we estimated Hedges' g and the corresponding SE for each study adopting a simulation approach based on a linear regression model (John et al., 2018) . In detail, to test the additive model pooled Hedges' g was computed with a fixed-effect model or random-effect model in case of significant heterogeneity among studies.
Results
Study selection and study characteristics
A total of 1051 items were identified (Fig. 1 ). After removing 167 duplicates using Endnote software (EndNote X 6.0.1, Thomson Reuters, USA, California State University) and 45 duplicates manually, the titles and abstracts of 839 paper were scrutinized. The reference lists of relevant reviews were hand-searched. Fifty-nine articles were assessed for eligibility. Fifteen articles were excluded because they did not fulfill the inclusion criteria. Data extraction was not possible in the case of 10 articles (Daelemans et al., 2004; De Castro et al., 2004; D'alva et al., 2005; Livshyts et al., 2009; Lazaros et al., 2012; Boudjenah et al., 2014; Colognato et al., 2014; Almawi et al., 2015; Laisk-Podar et al., 2015; Valkenburg et al., 2015) , because COS and ART were not evaluated in relation to polymorphism genotype expression. Data duplication was detected in studies by Desai et al. (2011 Desai et al. ( , 2013 and by Mohiyiddeen and collaborators (Mohiyiddeen et al., 2013a; 2013b) . Of these, we included two studies in our analysis (Desai et al., 2011; Mohiyiddeen et al., 2013b) . We extracted data regarding MII oocytes from the Mohiyiddeen et al. (2013a) study that were not reported in their subsequent paper (Mohiyiddeen et al., 2013b) . Thirty-three studies were included in our quantitative and qualitative analysis ( Fig. 1 and Table I ). Seven polymorphisms were reported in these studies: FSHR 919 G>A (rs 6165), FSHR 2039 G>A (rs6166), FSHR −29 G>A (rs1394205), LHB 82 T>C (rs1800447), LHB 1502 G>A (rs1056917), LHCGR 935 A>G (rs2293275) and LHCGR 3442-25 260 A>G (rs13405728).
Risk of bias within studies
Bias assessment within studies is shown in Table I . A high rate of agreement, evaluated by k-Cohen calculation, was observed between the two authors (A.C. and D.S.; k-Cohen = 0.83).
Summary of results
The results of the quantitative analysis of each outcome measure according to genotype distribution are reported below and summarized in Table II .
FSH consumption
A meta-analytic approach was possible only for FSHR (rs6165), FSHR (rs6166) and FSHR (rs1394205). No data were found regarding LHB (rs1056917). Four studies (Laven et al., 2003; Achrekar et al., 2009a; Genro et al., 2012; Yan et al., 2013) Fig. S1 ).
Eighteen studies (Perez Mayorga et al., 2000; Sudo et al., 2002; Laven et al., 2003; Behre et al., 2005; Jun et al., 2006; Loutradis et al., 2006; Achrekar et al., 2009a; Huang et al., 2010 Huang et al., , 2015 Nordhoff et al., 2011; Sheikhha et al., 2011; Anagnostou et al., 2012; Genro et al., 2012; Lledo et al., 2013; Yan et al., 2013; Mohiyiddeen et al., 2013b; Lindgren et al., 2016; Lledó et al., 2016) Fig. S2 ).
Three studies (Achrekar et al., 2009b; Desai et al., 2011; Tohlob et al., 2016) , for a total of 709 women, evaluated FSH consumption according to the FSHR (rs1394205) genotype. The consumption of FSH was significantly lower in FSHR GG homozygotes than in FSHR AA homozygotes (Random WMD: −1294.61 IU, 95% CI: −1996.14 to −593.08, P < 0.001, Bonferroni adjusted P = 0.008, I 2 = 99%), whereas no differences were observed between GG and AG heterozygotes (Random WMD: −277.84 IU, 95% CI: −1145.28 IU to 589.60, I 2 = 100%). FSH consumption was lower in AG heterozygotes than in FSHR AA homozygotes (Random WMD: −1014.36 IU, 95% CI: −1664.61 to −364.11, P = 0.002, Bonferroni adjusted P = 0.006, I 2 = 99%) (Fig. 2 ).
Two studies (Alviggi et al., 2011; Alviggi et al., 2013) reported FSH consumption according to LHB (rs1800447) genotype distribution. Both reported a significantly higher FSH consumption in variant carriers compared with wild-type carriers. One study (Lindgren et al., 2016) reported FSH consumption in relation to the distribution of the LHCGR (rs2293275) genotype. No significant differences among genotypes were detected.
One study (Yin et al., 2015) reported FSH consumption in relation to the distribution of the LHCGR (rs13405728) genotype. No significant differences among genotypes were reported.
The overall effect estimated by the analyses indicated that FSH consumption was only affected by the presence of FSHR (rs1394205). However, these results may be conservative given the high heterogeneity among trials and the relatively small number of patients evaluated.
Stimulation duration
A meta-analytic approach regarding stimulation duration was possible only for FSHR (rs6165) and FSHR (rs6166). No data on the other polymorphisms were found.
Three studies (Laven et al., 2003; Genro et al., 2012; Yan et al., 2013 ) for a total of 679 patients, evaluated stimulation duration in relation to the distribution of the FSHR (rs6165) genotype. The duration of stimulation did not differ between FSHR AA homozygotes and GG homozygotes (Random WMD: −0.59, 95% CI: −1.24 to 0.05, I 2 = 60%), however it was significantly shorter in AA than in Fig. S3 ). In summary, the only difference observed was a shorter duration of stimulation in FSHR (rs6165) AA homozygotes than in AG heterozygotes.
Number of oocytes retrieved
A meta-analytic approach was possible only for FSHR (rs6165), FSHR (rs6166) and FSHR (rs1394205). No data were found regarding LHCGR (rs2293275).
Five studies (Achrekar et al., 2009a; Genro et al., 2012; Lazaros et al., 2013; Yan et al., 2013; Trevisan et al., 2014) , for a total of 1020 women, reported the number of oocytes retrieved in relation to the distribution of the FSHR (rs6165) genotype. The number of oocytes retrieved was significantly higher in AA homozygotes than in either GG homozygotes (Fixed WMD: 1.85, 95% CI: 0.85-2.85, P < 0.001, Bonferroni adjusted P = 0.008, I 2 = 0%). No difference was detected among AG heterozygotes, GG homozygotes (Fixed WMD: −0.37, 95% CI: −1.51 to 0.78, I 2 = 18%) and AA homozygotes (Random WMD: 1.62, 95% CI: 0.28-2.95, P = 0.02, Bonferroni adjusted P = 0.052, I 2 = 56%) (Fig. 4 ). The additive model was marginally significant in the association between FSHR (rs6165) and number of oocytes retrieved (pooled Hedges' g −0.129; Fixed: 95% CI −0.258 to 0.000, P = 0.05, I 2 = 43%).
Twenty-one studies (Perez Mayorga et al., 2000; Sudo et al., 2002; De Castro et al., 2003; Behre et al., 2005; Jun et al., 2006; Klinkert et al., 2006; Loutradis et al., 2006; Achrekar et al., 2009a; Huang et al., 2010 Huang et al., , 2015 Nordhoff et al., 2011; Sheikhha et al., 2011; Genro et al., 2012; Lazaros et al., 2013; Lledo et al., 2013 Lledo et al., , 2016 Yan et 2 = 76%), but it was similar to that retrieved from AG heterozygotes (Random WMD: −0.18, 95% CI: −0.84 to 0.48, I 2 = 85%). The number of oocytes was significantly higher in AG heterozygotes than in GG homozygotes (Random WMD: 0.88, 95% CI: 0.12-1.63, P = 0.02, Bonferroni adjusted P = 0.04, I 2 = 76%) (Fig. 5 ).
The additive model was not significant for the association between FSHR (rs6165) and number of oocytes retrieved (pooled Hedges' g −0.072 95% CI −0.179 to 0.035, P = 0.19, I 2 = 65%).
Three studies (Achrekar et al., 2009b; Desai et al., 2011; Tohlob et al., 2016) , including 709 women, evaluated the number of oocytes retrieved in relation to the distribution of the FSHR (rs1394205) genotype. The number of oocytes retrieved was lower, albeit not significantly lower, in FSHR (rs1394205) AA homozygotes than in either GG homozygotes (Random WMD: −5.20, 95% CI: −11.22 to 0.82, I 2 = 99%) or AG heterozygotes (Random WMD: −3.88, 95% CI: −7.93 to 0.18, I 2 = 98%). No differences were observed between GG homozygotes and AG heterozygotes (Random WMD: −1.29, 95% CI: −3.51 to 0.93, I 2 = 97%) ( Supplementary Fig. S4 ).
Two studies (Alviggi et al., 2011; Alviggi et al., 2013) reported the number of oocytes retrieved in relation to the distribution of the LHB (rs1800447) genotype. In both studies, the number of oocytes retrieved did not differ among genotypes.
Figure 3 Forest plots of differences among FSHR (rs6165) genotype carriers in relation to stimulation duration. (A) (rs6165) A homozygotes versus G homozygotes. (B) (rs6165) A homozygotes versus heterozygotes. (C) (rs6165) heterozygous versus G homozygotes.
Only one study (Davar et al., 2014) reported the number of oocytes retrieved in relation to the LHB (rs1056917) genotype, and no significant differences among genotypes were observed.
Similarly, only one study (Yin et al., 2015) reported the number of oocytes retrieved in relation to the distribution of the LHCGR (rs13405728) genotype, and there were no significant differences among genotypes.
The overall effect size indicates that the FSHR (rs6165) and FSHR (rs6166) genotypes impacted on the number of oocytes retrieved. In both cases, AA homozygosity was associated with a higher number of oocytes retrieved, whereas GG homozygotes exerted an opposite effect. The effect size estimated for the FSHR (rs6166) genotype may be conservative because of the high heterogeneity.
Number of MII oocytes
A meta-analytic approach was possible only in the case of FSHR (rs6166). No data were found regarding LHB (rs1056917).
Only two studies (Genro et al., 2012; Trevisan et al., 2014) evaluated the number of MII oocytes retrieved in relation to FSHR (rs6165). In both studies, the number of MII oocytes did not differ among genotypes.
Five studies (Genro et al., 2012; Mohiyiddeen et al., 2013a; Trevisan et al., 2014; Lindgren et al., 2016; Lledó et al., 2016) including 1185 patients, reported the number of MII oocytes retrieved in relation to the distribution of the FSHR (rs6166) genotype. The number of MII oocytes was higher in AA homozygotes than in GG homozygotes but the differences did not reach statistical significance after Bonferroni correction (Fixed WMD: 1.03, 95% CI: 0.01-2.05, P = 0.05, Bonferroni adjusted P = 0.14, I 2 = 0%). No significant differences were observed between AA homozygotes and AG heterozygotes (Fixed WMD: 0.79, 95% CI: −0.05 to 1.62, I 2 = 0%), or between GG homozygotes and AG heterozygotes (Fixed WMD: 0.34, 95% CI: −0.57 to 1.26, I 2 = 49%) ( Supplementary Fig. S5 ).
Only two studies (Desai et al., 2011; Dan et al., 2015) reported the number of MII oocytes in relation to the distribution of the FSHR (rs1394205) genotype. In detail, Dan et al. (2015) observed a significantly higher number of MII oocytes in GG carriers than in AG/AA carriers. Similarly, Desai et al. (2011) found a significantly higher number of MII oocytes in GG carriers than in AG and AA carriers.
The only study to report the number of MII oocytes retrieved in relation to the LHB (rs1800447) genotype did not find any difference between wild-type and variant carriers . Similarly, the only study to report the number of MII oocytes retrieved in relation to the LHCGR (rs2293275) genotype did not find any difference among the haplotypes identified (Lindgren et al., 2016) . The only study to report the number of MII oocytes retrieved in relation to the distribution of the LHCGR (rs13405728) genotype did not find any differences among genotypes (Yin et al., 2015) .
The overall effect size indicates that the FSHR (rs6166) genotype did not significantly affect the number of mature oocytes retrieved. However, given the limited number of studies available, these observations should be viewed with caution.
OPR
A meta-analytic approach to OPR was possible only for FSHR (rs6166). No data were found regarding the FSHR (rs6165), LHB (rs1056917) or LHCGR (rs13405728) genotypes.
Seven studies (Jun et al., 2006; Sheikhha et al., 2011; Lledo et al., 2013; Mohiyiddeen et al., 2013b; Huang et al., 2015; Lindgren et al., 2016; Alviggi et al., 2016a) Fig. S6 ). Only two studies (Achrekar et al., 2009b; Tohlob et al., 2016) reported OPR in relation to FSHR (rs1394205). Achrekar et al. (2009b) reported a comparable OPR among GG, AG and AA carriers, whereas Tohlob et al. (2016) reported a higher OPR in women carrying the A allele than in those carrying the G allele (crude OR 1.32, 95% CI 1.01-1.74, P = 0.04), but this association was not significant when adjusted for the number of embryos transferred.
The only study to report OPR in relation to LHB (rs1800447) did not find any difference between wild-type and variant carriers .
Only one study (Lindgren et al., 2016) reported OPR in relation to LHCGR (rs2293275). Differences in terms of OPR were observed among haplotypes (AA: 18%; AG: 27%; GG: 31%, P = 0.037), with a higher prevalence in GG carriers.
Risk of bias across studies
The risk of significant bias across studies regarding the primary outcome was rejected by Egger's test (P = 0.828 for FSHR rs6166; P = 0.27 for FSHR rs6165, and P = 0.12 for FSHR rs1394205), visual inspection of the funnel plots, and the trim and fill method (Supplementary Fig. S7 ).
Subgroup and sensitivity analyses
We estimated the number of oocytes retrieved according to type of gonadotrophin, namely recombinant versus urinary FSH (Fig. 6) . We did not include papers in which both gonadotrophins were used for COS Jun et al., 2006; Huang et al., 2010; Sheikhha et al., 2011; Mohiyiddeen et al., 2013b) or in which the formulation adopted was not clearly stated (Achrekar et al., 2009a) . While a higher number of oocytes were retrieved in AA FSHR (rs6166) carriers than in GG carriers when recombinant FSH was used (Fixed WMD 1.15, 95% CI 0.53-1.76, P = 0.0003, Bonferroni adjusted 0.0009, I 2 = 43%) no differences were observed when urinary gonadotrophin was used (Random WMD 0.68, 95% CI: −2.19 to 3.54; I 2 = 86%). Concerning the FSHR (rs6165) genotype, FSH basal levels did not differ among haplotypes after Bonferroni correction ( Supplementary Fig. S8 ). On the other hand, FSH basal levels were significantly lower in AA than in GG FSHR (rs6166) carriers (Fixed WMD −0.54, 95% CI −0.72 −0.36, P < 0.00001, Bonferroni adjusted P < 0.0001, I 2 = 21%) (Fig. 7) .
Lastly, sensitivity analysis revealed that the pooled effect sizes were affected only with regard to the number of retrieved oocytes between FSHR (rs6165) AA and AG carriers (Supplementary Table II) .
Discussion
Summary of evidence
We conducted this systematic review in the attempt to unravel the role of gene polymorphisms of gonadotrophins and their receptors on the outcome of COS. We evaluated OPR rather than live birth rate because the many features that can affect the later stages of pregnancy may confound the impact of folliculogenesis-related polymorphisms. Our findings indicate that FSHR polymorphisms affect the outcome of COS. In particular, FSH consumption was higher in A allele homozygous carriers of the FSHR (rs1394205) genotype. Furthermore, the number of oocytes retrieved was significantly higher in FSHR (rs6165) AA carriers, and ovarian stimulation was significantly shorter in these patients than in GG and AG carriers. Similarly, the number of oocytes retrieved was significantly higher in FSHR (rs6166) AA carriers than in GG carriers. Although neither polymorphism had an additive effect, a significant impact on the number of oocytes was observed under co-dominance (AA versus GG and AG versus GG) for FSHR rs6166 and only under homozygote models (AA versus GG) for FSHR rs6165. Therefore, both FSHR polymorphisms seem to influence responsiveness to COS treatment.
Gonadotrophin type seems to affect the number of oocytes retrieved in relation to FSHR (rs6166) genotype distribution. In fact, the number of oocytes retrieved was significantly higher in AA carriers than in GG carriers when recombinant FSH was used but not when urinary FSH was used. FSHR (rs6166) also affects endogenous levels of FSH as shown by the finding of higher plasma FSH values in GG carriers than in AA carriers. Lastly, the FSHR (rs6166) genotype did not significantly affect OPR.
The results of our review of gonadotrophins and their receptor polymorphisms conducted with a quantitative approach are consistent with those reported in qualitative reviews (Altmae et al., 2011) . However, it remains to be determined whether a pharmacogenomic approach could counteract the effect of such polymorphisms. Behre et al. (2005) partially addressed this issue by stratifying normogonadotrophic patients according to the distribution of the FSHR (rs6166) genotype, and found that increasing daily FSH dose from 150 to 225 IU/day counteracted the lower estradiol levels in GG carriers.
Given the paucity of data, we were unable to carry out a metaanalysis of remnant gonadotrophins and their receptor polymorphisms [LHB (rs1800447), LHB 1502 G>A (rs1056917), LHCGR 935 A>G (rs2293275) and LHCGR 3442-25 260 A>G (rs13405728)].
In summary, our meta-analysis demonstrates that specific polymorphisms of gonadotrophins and their receptors modulate the ovarian response to exogenous FSH. On the other hand, further studies are required to evaluate the impact of these polymorphisms on OPR and live birth rate. In this context, it is noteworthy that ART births are greatly influenced by various factors, most of which occur during the late stages of pregnancy and transcend the 'physiological' effects of gonadotrophins and their receptors. In other words, we maintain that the ovarian response is more reliable than pregnancy rate in determining the effect of gonadotrophins and their receptor polymorphisms on COS.
Interpretation of results and clinical considerations
Our findings can be related to the molecular characteristics of the genotypes associated with the response to COS (Table III) . The FSHR gene carries more than 2000 SNPs, although only FSHR (rs6165) and FSHR (rs6166) seem to play a prominent role in the response to COS. Both SNPs cause an amino acid exchange: in FSHR (rs6166), asparagine is substituted by serine thereby introducing a potential phosphorylation site, whereas in FSHR (rs6165) threonine is substituted by alanine, which results in a change from a polar to a nonpolar hydrophobic amino acid thereby removing a potential O-linked glycosylation site. These genotypes are in nearly complete linkage disequilibrium, except in some African populations Casarini et al., 2015) . In vitro studies conducted using human granulosa cells showed that GG carriers of the FSHR (rs6166) genotype have greater resistance to FSH than do AA carriers (Casarini et al., , 2015 . Our findings corroborate these previous observations. Indeed, we found that GG FSHR (rs6166) carriers had higher ovarian resistance to exogenous gonadotrophin and consequently had fewer oocytes compared with AA carriers. Moreover, we demonstrate that such FSHR resistance involves also endogenous FSH levels, as reported elsewhere (Fig. 7) (Mohiyiddeen and Nardo, 2010) . These effects corroborate the potential impaired function of FSHR in G allele carriers and could explain why GG allele carriers have an impaired prognosis to COS as fewer oocytes are collected in these patients. FSHR function is controlled in both men and women by another FSH beta subunit (rs10835638) polymorphism (Grigorova et al., 2010; Ferlin et al., 2011; La Marca et al., 2013) , which is significantly correlated with FSH beta subunit transcriptional activity and metabolism (Hoogendoorn et al., 2003) . There is also evidence that FSHR (rs6166) could interact with polymorphisms that influence ART outcomes. Indeed, in a large cohort study, FSHR (rs6166) and LHCGR (rs2293275) allele G carriers had a 4-fold increased chance of pregnancy versus A carriers of both polymorphisms. Moreover, the number of mature oocytes was significantly higher in subjects with FSHR (rs1394205) GG plus FSHR (rs6166) AA genotypes than in other genotype combinations of these polymorphisms (Desai et al., 2013) .
The finding of Borgbo et al. (2015) that FSHR (rs6166) and FSHR (rs6165) GG carriers had higher LHCGR gene expression but lower anti-Mullerian hormone (AMH) receptor-2 expression versus carriers of other haplotypes suggested that these polymorphisms could affect the protein expression of human antral follicles. Nonetheless, it remains to be established whether FSHR (rs6166) and FSHR (rs6165) affect FSHR protein expression. Despite the linkage disequilibrium between FSHR (rs6165) and FSHR (rs6166), we decided to report the two polymorphisms separately for two reasons. Firstly, as stated above, the linkage disequilibrium between them is not universal . Secondly, they seem to be associated with different COS outcomes. For instance, Achrekar et al. (2009a) detected significant differences in terms of total FSH consumption among FSHR (rs6165) genotypes but not among FSHR (rs6166) genotypes. In addition, Trevisan et al. (2014) observed that only the FSHR (rs6165) genotype influences the number of embryos produced. Thus, these studies suggest that, although in linkage disequilibrium, these two polymorphisms could influence COS outcome in a different way.
The FSHR (rs1394205) polymorphism located in the 5′-untranslated region of the gene has been extensively studied in association with ovarian response. In Chinese hamster ovary cells, the transcription activity of FSHR was significantly lower in A allele carriers than in G allele carriers (Nakayama et al., 2006) . In another study, even the expression of FSHR was significantly lower in AA than in GG carriers (Desai et al., 2011 ). Furthermore, the relative level of protein expression and membrane receptor expression in cumulus cells was significantly lower in AA carriers than in carriers of other haplotypes (Desai et al., 2011) . Consequently, basic science evidence suggests that the postulated role of FSHR (rs1394205) is more relevant in modulating FSHR protein function versus FSHR (rs6166) and FSHR (rs6165). At clinical level, we observed that FSHR (rs1394205) AA carriers have a higher FSH consumption in COS than carriers of the GG and AG haplotypes, and therefore, AA carriers may have an impaired response to ovarian stimulation.
Limitations and strengths
Like all meta-analyses, our study has several limitations. First, most of the studies included were observational and retrospective, and thus more prone to bias. Second, the number of studies evaluating COS outcomes in relation to the patient's gonadotrophin receptor genotype is relatively small. Third, it was not possible to evaluate the effect of alternate alleles on our findings because most trials did not evaluate more than one SNP simultaneously. Fourth, the studies included in our review were highly heterogeneous. This could be probably explained by the wide variation in terms of populations and treatment strategies. Lastly, OPRs were inconsistently reported in the included studies, however, we were able to conduct a metaanalysis for OPR with regard to the FSHR (rs6166), involving an elevated number of observations (over 3000 patients). We used several strategies to overcome these limitations. First, we applied random-effect model to strengthen the validity of our results in case of substantial heterogeneity among trials. Furthermore, we conducted a sensitivity analysis in which we considered only papers with a low risk of bias, namely those with a NOS score above 6. The observed pooled effect sizes did not differ significantly from the overall analysis except in a few cases. Hence, the consistency in the direction of our findings is reliable and the methods were applied rigorously.
Future research
The pharmacogenomic approach to medical care is becoming a reality in several fields, notably for patients at a high risk of adverse drug reactions (Sychev and Malova, 2015) . In the ART setting, a pharmacogenomic approach to COS could lead to better standardization of treatment, thereby increasing the chance of ART success and reducing a potentially life-threatening excessive ovarian response.
Remarkably, no large randomized clinical trial on this topic has yet been conducted notwithstanding the relatively high number of studies published over the last 20 years. We believe that the pharmacogenomic approach to COS is still a largely neglected topic in the reproductive field. Furthermore, it noteworthy that most of the polymorphisms reported in our review are widespread in the general population and in women with reproductive disorders (Nilsson et al., 1997; Alviggi et al., 2009 Alviggi et al., , 2015 Simoni and Casarini, 2014) , and that genotype analysis can now be provided at the same costs of other commonly used analyses (e.g. AMH, antral follicle count).
Conclusion
Our systematic review indicates that specific SNPs of the gonadotrophins and their receptors influence COS outcomes. This evidence is supported by a large number of trials mainly devoted to FSHR (rs6165) and FSHR (rs6166) polymorphisms. Our analysis shows that a higher FSH consumption is expected in homozygotes for the A allele of the FSHR (rs1394205) polymorphism than carriers of the G allele. Moreover, FSHR (rs6166) GG homozygotes seem to be less responsive to COS treatment. In fact, they have fewer oocytes than do AA and AG carriers. It is feasible that the effect of these polymorphisms on COS may partially explain the phenomenon of 'hypo-response' that has been reported in 10-15% of normogonadotrophic ART women (Alviggi et al., 2006; . This peculiar ovarian response profile was recently included in the new classification of low prognosis women (Humaidan et al., 2016; Poseidon et al., 2016) . Given the overall effect of gonadotrophins and their receptor SNPs on COS, a pharmacogenomic approach seems a promising strategy with which to improve the clinical management of infertile women candidates for COS.
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